ADVERTISEMENT

Buy, Sell Or Hold: Maruti Suzuki, Motilal Oswal, Samvardhana Motherson, Piramal Pharma — Ask Profit

Analysts also shared insights on the share prices of Indian Renewable Energy Development Agency, NMDC and IRB Infrastructure Developers.

<div class="paragraphs"><p>Analysts shared insights on the share prices of&nbsp;Maruti Suzuki India,&nbsp;Motilal Oswal&nbsp;Financial Services, Samvardhana Motherson International,&nbsp;Piramal Pharma,&nbsp;Indian Renewable Energy Development Agency (Ireda), NMDC and IRB Infrastructure Developers (Buy, Sell Or Hold. Image by starline on Freepik)</p></div>
Analysts shared insights on the share prices of Maruti Suzuki India, Motilal Oswal Financial Services, Samvardhana Motherson International, Piramal Pharma, Indian Renewable Energy Development Agency (Ireda), NMDC and IRB Infrastructure Developers (Buy, Sell Or Hold. Image by starline on Freepik)

Should you buy shares of Maruti Suzuki India Ltd. at the current market price? Is NMDC Ltd. a good choice from a long-term perspective? Should you keep holding shares of Indian Renewable Energy Development Agency Ltd.?

Girish Sodhani, co-founder of Ensure Capital, and Aditya Arora, founder and research analyst of Adlytick, answered these investor queries and more on NDTV Profit's Ask Profit show.

Maruti Suzuki (CMP: Rs 11,730)

Arora: Recovery Expected

  • Recovery can be expected.

  • Technically has reached its support of Rs 11,000-odd levels.

  • Unless Rs 11,200 is protected, we can expect recovery in this counter.

  • Once the stock moves above Rs 11,850, that will be a technical breakout.

Opinion
Maruti Suzuki Effects Third Price Hike This Year To Offset Rising Input Costs

Motilal Oswal (CMP: Rs 636.25)

Arora: Buy

  • Stock looks good right now.

  • Seen significant correction.

  • Risk-reward ratio is good.

  • Buy at stop loss of Rs 550.

Samvardhana Motherson (CMP: Rs 508.50 )

Sodhani: Buy

  • Stock has come into order ancillaries.

  • Buy and hold for four to five years.

Opinion
Trade Setup For March 21: Nifty Support Near 22,940–22,974

Piramal Pharma (CMP: Rs 221.29)

Sodhani: Buy

  • Bit bullish on fundamental terms.

  • Focusing on expansions, restructuring propositions of growth and export numbers.

  • Add at Rs 200–205 range, hold for three years.

Arora: Buy

  • Medium-term trend is up.

  • Might continue upward journey once there is a breakout of Rs 230.

  • Buy on dips.

Opinion
Piramal Pharma Is Jefferies' Top Pick Among Contract Manufacturers With Sector Outlook Positive

Ireda (CMP: Rs 149.96 )

Sodhani: Hold

  • Maintain a thought of a time frame of a minimum of five years for renewable energy stocks.

  • Company's fundamentals look good, strong quarters and profit growth.

  • Market corrections are there but this sector has settled down.

  • Stay invested for at least two to three years.

Opinion
Ireda Hikes FY25 Borrowing Limit By Rs 5,000 Crore

NMDC (CMP: Rs 68.79)

Arora: Buy

  • Fundamental outlook is pretty good.

  • Technically has given a breakout about levels of Rs 65.

  • Go for recovery till levels like Rs 75–80.

  • Buy at stoploss of Rs 60.

Sodhani: Avoid At Current Levels

  • Not a good bet as of now.

  • Heavy volatilty in the sector.

  • Avoid at current levels.

  • If it reaches Rs 49 or Rs 50 levels, buy it.

Opinion
NMDC Price Targets Cut By Analysts On Lower Volume, Increased Competition

IRB Infrastructure Developers (CMP: Rs 45.88 )

Arora: Buy

  • Risk-reward ratio is very attractive.

  • Important support for the counter is Rs 40.

  • Buy with a stop loss of Rs 40.

Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult with their own financial or investment adviser before taking any investment decision.

Opinion
Stock Market Highlights: Nifty, Sensex End At Over One-Month High; Bharti Airtel, TCS Top Gainers
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit